Overview

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Phase:
PHASE1
Details
Lead Sponsor:
University of Minnesota
Treatments:
cytomegalovirus-specific hyperimmune globulin